The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries
Open accessAbstract
Objectives: To assess the effects of costs on access to medicines in 11 developed countries offering different levels of prescription drug coverage for their populations. Design: Cross-sectional study of data from the Commonwealth Fund 2014 International Health Policy Survey of Older Adults. Setting: Telephone survey conducted in 11 high-income countries: Australia, Canada, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the UK and the USA. Participants: 22 532 adults aged 55 and older and living in the community in studied countries. Primary outcome measure: Self-reported cost-related non-adherence (CRNA) in the form of either not filling a prescription or skipping doses within the last 12 months because of out-of-pocket costs. Results: Estimated prevalence of CRNA among all older adults varied from <3% in the France, Norway, Sweden, Switzerland and the UK to 16.8% in the USA. Canada had the second highest national prevalence of CRNA (8.3%), followed by Australia (6.8%). Older adults in the USA were approximately six times more likely to report CRNA than older adults in the UK (adjusted OR=6.09; 95% CI 3.60 to 10.20). Older adults in Australia and Canada were also statistically significantly more likely to report CRNA than older adults in the UK. Across most countries, the prevalence of CRNA was higher among lower income residents and lower among residents over age 65. Conclusions: Observed differences in national prevalence of CRNA appear to follow lines of availability of prescription drug coverage and the extent of direct patient charges for prescriptions under available drug plans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well established that high prices are barriers to access to medications, particularly for AOMs [12].”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revisiting the Behavioral Model and Access to Medical Care: Does it Matter?
Andersen, R. M. (1995) · Journal of Health and Social Behavior · doi:10.2307/2137284 · Cited by 9,831
DiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169
Factors affecting therapeutic compliance: A review from the patient’s perspective
Li, S.-C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1458 · Cited by 1,290
Prescription Drug Cost Sharing
Goldman, D. P., Joyce, G., & Zheng, Y. (2007) · JAMA · doi:10.1001/jama.298.1.61 · Cited by 890
Patients At-Risk for Cost-Related Medication Nonadherence: A Review of the Literature
Briesacher, B. A., Gurwitz, J. H., & Soumerai, S. B. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0180-x · Cited by 389
The effect of cost on adherence to prescription medications in Canada
Law, M. R., Cheng, L., Dhalla, I. A., Heard, D., & Morgan, S. G. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.111270 · Cited by 232
Self-citationOsborn, R., Moulds, D., Squires, D. A., Doty, M. M., & Anderson, C. (2014) · Health Affairs · doi:10.1377/hlthaff.2014.0947 · Cited by 212
Pharmaceutical policies: effects of cap and co-payment on rational drug use
Austvoll‐Dahlgren, A., Aaserud, M., Vist, G. E., Ramsay, C. R., Oxman, A. D., Sturm, H., Kösters, J. P., & Vernby, Å. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007017 · Cited by 166
Prescription Drug Insurance Coverage and Patient Health Outcomes: A Systematic Review
Kesselheim, A. S., Huybrechts, K. F., Choudhry, N. K., Fulchino, L. A., Isaman, D. L., Kowal, M. K., & Brennan, T. A. (2014) · American Journal of Public Health · doi:10.2105/ajph.2014.302240 · Cited by 83
Kennedy, J. J., & Morgan, S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.07.009 · Cited by 71
Self-citation
Cited by
Sorted by citations
Medications safety pharmacoeconomics-related issues
Al‐Worafi, Y. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819837-7.00016-9 · Cited by 367
Sendekie, A. K., Netere, A. K., Kasahun, A. E., & Belachew, E. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274971 · Cited by 127
The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey
Law, M. R., Cheng, L., Kolhatkar, A., Goldsmith, L. J., Morgan, S. G., Holbrook, A. M., & Dhalla, I. A. (2018) · CMAJ Open · doi:10.9778/cmajo.20180008 · Cited by 88
Self-citationBhattarai, B., Walpola, R. L., Mey, A., Anoopkumar‐Dukie, S., & Khan, S. A. (2020) · Respiratory Care · doi:10.4187/respcare.07355 · Cited by 79
Levi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity · doi:10.1002/oby.23725 · Cited by 69
“It is well established that high prices are barriers to access to medications, particularly for AOMs [12].”
Background
Metadata
- Authors
- Morgan, S. G., & Lee, A.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- Morgan, Steven G
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2017-01
- Volume
- 7
- Issue
- 1
- Pages
- e014287
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5293866
- OpenAlex
- W2583329548
- Cited by
- 112
- References
- 16
- Citations by year
- 2026: 1 · 2025: 12 · 2024: 5 · 2023: 16 · 2022: 12 · 2021: 17 · 2020: 20 · 2019: 13 · 2018: 7 · 2017: 9
- FWCI
- 24.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Commonwealth Fund (20160646)
- Institute of Gender and Health (DCO150GP)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Keywords
- cost-related nonadherence, medication adherence, older adults, prescription drug coverage, out-of-pocket costs, access to medicines, income inequality, cross-national comparison
- MeSH terms
- Assessment of Medication Adherence, Aged, Australia, Canada, Cross-Sectional Studies, Europe, Health Expenditures, Female, Humans, Income, Insurance, Pharmaceutical Services, Male, Middle Aged, New Zealand, Surveys and Questionnaires, United States, Drug Monitoring, Cost of Illness, Developed Countries, Insurance Coverage, Universal Health Insurance, Medication Adherence, Prescription Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
